VIA Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of compounds for the treatment of cardiovascular diseases. The company is headquartered in San Francisco, California and currently employs 6 full-time employees. The company went IPO on 2000-04-18. The Company’s lead compound, VIA-2291, targets an unmet medical need of reducing atherosclerotic plaque inflammation, which is an underlying cause of atherosclerosis and its complications. Atherosclerosis is a cardiovascular disease that results from chronic inflammation and the build-up of plaque in arterial blood vessel walls. The Company’s clinical development strategy integrates several technologies to provide clinical proof-of-concept, as early as possible in the clinical development process. These technologies include the measurement of biomarkers, medical imaging of the coronary and carotid vessel walls to evaluate the plaque characteristics, and atherosclerotic plaque bioassays.
Follow-Up Questions
VIA Pharmaceuticals Inc (VIAP) の株価収益率はいくらですか？
VIA Pharmaceuticals Inc の株価収益率は 0 です。
VIA Pharmaceuticals Inc のCEOは誰ですか？
Dr. Lawrence Cohen は VIA Pharmaceuticals Inc の President で、2007 から在籍しています。
VIAP の株価パフォーマンスは？
VIAP の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
VIA Pharmaceuticals Inc の主な事業テーマや業界は？
VIA Pharmaceuticals Inc は Biotechnology 業界、セクターは Health Care に属しています。
